IFNA2 and hepatitis C virus infection: This intrinsic resistance might be caused by somatic changes already present at treatment start or constitutive germline variants, such as in the case of hepatitis C therapy where IL28B was significantly associated with the response to IFNα and ribavirin 35–37.